Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...

Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author ...

Share on Pinterest Researchers believe that high doses of semaglutide may reduce blood flow to the optic nerve, which could lead to eye stroke. Maria Korneeva/Getty Images A new study has found that ...

Your doctor will help you decide which form, pill or injection, of Wegovy is best for you. It may depend on your medical history, which dosing schedule fits your lifestyle better, and how comfortable ...

The Guardian reported on the 7th that research has found weight loss injections like Wegovy can be produced for as little as $3 per month. The report states that if semaglutide, the active ingredient ...

Downside to dropping pounds? The new pill form of popular GLP-1 drugs contains a compound that could cause troubling side ...

For decades, researchers have been looking for an effective weight-loss pill. But the recent success of glucagon-like peptide-1 (GLP-1) weight-loss injections has sparked new hope — especially for ...

Unaided awareness rose sharply following approval. In February 2026, 60% of PCPs and 78% of endocrinologists cited the Wegovy pill as a top-of-mind weight loss therapy--up from just 14% and 11%, ...

By Stine Jacobsen and Maggie Fick COPENHAGEN, March 9 (Reuters) - Novo Nordisk said on Monday it will sell its blockbuster Wegovy and Ozempic drugs through the U.S. telehealth company Hims & Hers ...

Battling to regain its market share over rival Eli Lilly, Novo Nordisk announced Tuesday that it will reduce the list prices of its popular weight loss drug Wegovy and diabetes drugs Ozempic and ...